Clinical Trials
Study Title:
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Upifitamab Rilsodotin (XMT 1536) as Post Platinum Maintenance Therapy for Participants with Recurrent, Platinum Sensitive Ovarian Cancer (UP NEXT)
|
For more information about the trial above please contact the study team:
|